Nuvectis Pharma Inc
Ownership
Ownership Structure
Who owns Nuvectis Pharma Inc (NVCT)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 65.0% of the shares are freely tradable; institutional investors hold 18.2%.
Largest Shareholders
Institutions
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| Perceptive Advisors LLC | 3.10 | 1,000,000 | +0.0 | 06/30/2026 |
| Soleus Capital Management, L.P. | 3.10 | 1,000,000 | +0.0 | 06/30/2026 |
| Iridian Asset Management LLC | 2.41 | 777,078 | +19.2 | 06/30/2026 |
| BlackRock Inc | 2.37 | 764,441 | -2.3 | 03/31/2026 |
| Vanguard Capital Management, LLC | 2.04 | 659,879 | +0.0 | 03/31/2026 |
| Occam Crest Management L.P. | 1.26 | 407,147 | +7.1 | 03/31/2026 |
| Geode Capital Management, LLC | 1.19 | 384,105 | +5.5 | 03/31/2026 |
| Baldwin Brothers Inc | 1.18 | 382,015 | +0.9 | 06/30/2026 |
Funds
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 2.02 | 650,487 | +0.0 | 07/31/2026 |
| iShares Russell 2000 ETF | 1.33 | 430,819 | -0.6 | 08/31/2026 |
Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.
Insider holdings
| Person | Role | Shares | Value | As of | Type |
|---|---|---|---|---|---|
| Carson Michael J. | Vice President, Finance | 230,118 | 5,062,596 $ | Aug 3, 2026 | direct |
Holdings as of each person's most recent SEC Form 4 filing — excluding options and RSUs, which are not shares yet. Holdings may have changed between two filings.
Insiders
Insider Transactions
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Aug 3, 2026 | Carson Michael J. | Vice President, Finance | Other | 30,000 | 0.00 | – |
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character. View all insider transactions →
Data as of: September 18, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.